Following release in March of positive topline results from a phase 3 trial of an investigational cannabidiol product (Epidiolex, GW Pharmaceuticals) in patients with Dravet syndrome, GW Pharmaceuticals has now announced more positive results, this time from a phase 3 study in patients with Lennox-Gastaut syndrome (LGS).
Like Dravet syndrome, LGS is a rare and severe form of epilepsy that begins in infancy or early childhood. Epidiolex is a liquid formulation of pure plant-derived cannabidiol, a nonpsychoactive component of the cannabis plant.
“From a physician’s perspective, the positive outcome in this trial of Epidiolex in patients with Lennox-Gastaut syndrome is very exciting,” said Linda Laux, MD, director of the Comprehensive Epilepsy Center at Ann Robert H. Lurie Children’s Hospital, Chicago, Illinois, and an investigator in the trial, in a press release.
LGS is particularly difficult to treat, and most patients don’t get an adequate response from existing therapies, said Dr Laux.